CSPC to launch Paxlovid ver­sion in Chi­na; SEC charges ex-Pfiz­er em­ploy­ee with in­sid­er trad­ing

Pfiz­er inked a deal with a Chi­nese phar­ma to launch a form of its Covid-19 an­tivi­ral Paxlovid in Chi­na.

The com­pa­ny is work­ing with CSPC Phar­ma­ceu­ti­cal Group, which is based in Shi­ji­azhuang, Chi­na, to pro­duce and launch a lo­cal brand of the an­tivi­ral, ac­cord­ing to a news re­lease. Bloomberg re­port­ed that Pfiz­er al­so has agree­ments with Mehe­co to sell the drug in Chi­na and Zhe­jiang Hua­hai Phar­ma­ceu­ti­cal to make and dis­trib­ute it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.